ClinicalTrials.gg
TerminatedNCT04026750Updated Apr 2, 2021Results posted

Insulin Tolerance Test Study in Patients With Type 1 Diabetes

A Phase 1 interventional study of Pitolisant in Type 1 Diabetes and Hypoglycemia, sponsored by High Point Clinical Trials Center. Terminated at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-04-02.

Sponsored by High Point Clinical Trials Center · Phase 1, Interventional, and Basic science

Why this study was terminated
Based on scientific data collected during the trial and high screen fail rate.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
5
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States — 191 open to participants now, 259 under way, 17 of them phase 3. Diabetes Mellitus, Type 1 · United States.

Enrollment
1,163rd of 1,242
5 · median 40
Started
2019
with 101 others
Phase 1
147 of 1,458
11 open now
Registered
967th of 1,458
by date

Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, this one is the 1,163rd largest by enrollment of the 1,242 interventional ones that give a count, is one of 102 that started in 2019, is one of 147 in phase 1, and was the 967th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

191 of the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States are open now. Recruiting first, the newest first:

186 more — sign in →

All 191 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to determine the safety, tolerability and pharmacodynamics of pitolisant in patients with Type 1 Diabetes

03

Conditions studied

  • Type 1 Diabetes
  • Hypoglycemia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Inclusion criteria: Diagnosis of diabetes => 4yrs, On Insulin => 4yrs, \<= 10%, At least one episode of severe hypoglycemia in past 12 months, fasting c-peptide \<0.7 ng/ml

Exclusion criteria

Exclusion Criteria:

  • Hypoglycemia unawareness, DKA within 3 months prior to randomization, Reduced renal function, Anxiety and depression
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Pitolisant

    Drug: Pitolisant

  • Placebo comparator
    Matching placebo

    Drug: Pitolisant

Interventions

  • Pitolisant will be administered orally for 7 days. Patients may have their study drug dose adjusted downward if the starting dose is not tolerated.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Peak Glucagon Response to Hypoglycemia

    Change in peak glucagon concentration from day 1 ITT (baseline) to day 7 ITT (on treatment). Serial glucagon collected during ITT's, occurred at -10, 0, 15, 30, 45, 60, 90, 120 and 180 minutes just prior to and during the ITT.

    Time frame: Change in peak glucagon during ITT Day 1 vs. Day 7

Secondary outcomes

  1. Number of Patients Returning to Blood Glucose =>70 mg/dL

    Number of patients that returned to blood glucose =\>70 mg/dL during ITT

    Time frame: Day 7

07

Results

Posted Apr 2, 2021

Participant flow

Participant flow — Overall Study
MilestonePitolisant 36mgPlacebo
Started32
Completed32
Not completed00

Outcome measures

PrimaryChange From Baseline in Peak Glucagon Response to Hypoglycemia

Change in peak glucagon concentration from day 1 ITT (baseline) to day 7 ITT (on treatment). Serial glucagon collected during ITT's, occurred at -10, 0, 15, 30, 45, 60, 90, 120 and 180 minutes just prior to and during the ITT.

Time frame:
Change in peak glucagon during ITT Day 1 vs. Day 7
Reported as:
Mean · pg/mL
Change From Baseline in Peak Glucagon Response to Hypoglycemia
pg/mLPitolisant 36mgPlacebo
Change From Baseline in Peak Glucagon Response to Hypoglycemia7.5 (-2.07 to 17.02)13.1 (2.08 to 24.07)
SecondaryNumber of Patients Returning to Blood Glucose =>70 mg/dL

Number of patients that returned to blood glucose =\>70 mg/dL during ITT

Time frame:
Day 7
Reported as:
Count of participants · Participants
Number of Patients Returning to Blood Glucose =>70 mg/dL
ParticipantsPitolisant 36mgPlacebo
Number of Patients Returning to Blood Glucose =>70 mg/dL10

Adverse events

Collected over Day 1 to day 16. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pitolisant 36mg0/3 (0%)0/3 (0%)3/3 (100%)
Placebo0/2 (0%)0/2 (0%)2/2 (100%)
Most frequent other events
Most frequent other events
EventPitolisant 36mgPlacebo
HypoglycemiaMetabolism and nutrition disorders3/32/2
DiarrhoeaGastrointestinal disorders1/30/2
Gastroenteritis viralInfections and infestations1/30/2
PresyncopeNervous system disorders1/30/2

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Pitolisant 36mgPlaceboTotal
<=18 years000
Between 18 and 65 years325
>=65 years000
Age, Continuous
Age, Continuous(years)Pitolisant 36mgPlaceboTotal
Mean32 ± 5.5743.5 ± 12.0236.6 ± 9.56
Sex: Female, Male
Sex: Female, Male(Participants)Pitolisant 36mgPlaceboTotal
Female011
Male314
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pitolisant 36mgPlaceboTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American000
White314
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Pitolisant 36mgPlaceboTotal
United States325
08

Study locations

1 site
  • High Point Clinical Trials Center
    High Point, North Carolina 27265, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2019 to primary completion in Feb 2020, 5 months.

Results were first posted in Apr 2021, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2019
First posted
Jul 19, 2019
StartActual
Sep 15, 2019
Primary completionActual
Feb 16, 2020
CompletionActual
Feb 16, 2020
Results first posted
Apr 2, 2021
Last update
Apr 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04026750
Lead sponsor
High Point Clinical Trials Center
Collaborators
Ferox Therapeutics
Responsible party
Sponsor
First posted
Jul 19, 2019
Start date
Sep 15, 2019
Primary completion
Feb 16, 2020
Completion
Feb 16, 2020
Results posted
Apr 2, 2021
Last update
Apr 2, 2021

Study contacts

Melanie Fein, MD
principal investigator · PI

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pitolisant

Start the discussion